CalciMedica (CALC) Insider Fred Middleton Buys $199K of Stock

Fred Middleton Buys Shares of CalciMedica Stock

Fred Middleton purchased 248,972 shares of CalciMedica, Inc. (NASDAQ:CALC) on June 25, 2026. The shares were acquired at a price of $0.80 each, bringing the total transaction value to approximately $199,177. The purchase was filed with the Securities and Exchange Commission.

Inside CalciMedica Stock and Recent Price Levels

The shares recently traded at $0.82, hovering near the low end of their 52-week range. That range spans from a low of $1.86 up to a high of $36.00. The stock currently trades below its 50-day moving average of $3.03 and its 200-day moving average of $7.75. CalciMedica carries a market capitalization of about $57.17 million.

Heavy Insider Buying on June 25

Middleton's purchase was part of a broader wave of insider buying at the firm on June 25, 2026, where several leaders added to their holdings at $0.80 per share. Robert Wilson bought 1,182,621 shares worth about $946,096. Eric Roberts, who serves as Chief Business Officer, bought 186,729 shares valued at roughly $149,383. Chief Executive Officer Rachel Leheny also picked up 186,729 shares for about $149,383. Finally, Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares for a total value of approximately $99,588.

Guggenheim Analyst Coverage and Targets

Analyst activity surrounds the firm as well. On August 20, 2026, Guggenheim initiated coverage on the equity with a Buy rating and set a price target of $9.00. Across the broader analyst community, the stock holds a mean price target of $50.00, with a high estimate of $75.00 and a low estimate of $30.00 based on opinions from 3 analysts.

Inside CalciMedica's Pipeline and Operations

CalciMedica is based in La Jolla, California, and operates as a clinical-stage biopharmaceutical firm. The company develops treatments for illnesses caused by inflammatory processes, immunologic conditions, and direct cellular damage. Its lead candidate, Auxora, is designed to inhibit calcium release-activated calcium channels for conditions like acute pancreatitis and severe pneumonia. The organization employs 15 people and maintains a current ratio of 5.58.

What to Watch Next for CALC

Investors will keep an eye on upcoming corporate updates and regulatory filings from the biotech firm. The next earnings report is expected around August 11, 2025. Market watchers will also track whether additional insiders adjust their holdings or if the stock recovers toward its moving averages.